For patients with early RA with aggressive progression

~2x as many patients receiving HUMIRA + MTX had no radiographic progression at 2 years vs MTX alone1

Chart depicting “PREMIER: Percentage of Patients With No Worsening in TSS”

In the above analysis, patients who withdrew or had missing values were considered nonresponders.

Mean change from baseline in Total Sharp Score (TSS) at 1 year (primary endpoint) was 5.7 for MTX-treated patients vs 1.3 in HUMIRA + MTX treatment group (P<0.001)

More HUMIRA + MTX patients showed no radiographic progression at 2 years (Δ TSS<0.5) vs MTX alone2

Chart depicting “PREMIER: Patients with no Radiographic Progression at 2 Years Based on ACR Response”

The above analysis is as observed at the indicated time points. Patients with missing data were excluded.
Nonresponser = <ACR20.

Across ACR responses, radiographic progression occurred significantly less frequently in HUMIRA + MTX patients at 2 years vs patients taking MTX alone

06G-64C-Q352-6

HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. HUMIRA can be used alone or in combination with methotrexate. HUMIRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in adult patients with psoriatic arthritis. HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Please see Important Safety Information. Serious and sometimes fatal side effects have been reported with HUMIRA, including tuberculosis and other serious infections.

Please see full prescribing information.

References: 1. Breedveld FC, Weisman MH, Kavanaugh AF, et al, for the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. 2. Genovese MC, Kavanaugh AF, Cohen SB, et al. The relationship of radiographic progression to clinical response in patients with early RA treated with adalimumab (HUMIRA^®) plus MTX or MTX alone. Presented at: American College of Rheumatology Annual Scientific Meeting; November 2005; San Diego, Calif.

Legal Notices/Privacy Policy. Copyright 2007, Abbott Laboratories, Abbott Park, Illinois, U.S.A. If you have any questions about Abbott's HUMIRA.com Web site that have not been answered click here. This Web site and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.